NASDAQ:RKDAArcadia Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcadia Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.64 +0.07 (+1.96 %) (As of 05/27/2020 04:00 PM ET) Add Compare Share Today's Range$3.46Now: $3.64▼$3.6850-Day Range$2.94MA: $3.93▼$5.0652-Week Range$1.82Now: $3.64▼$10.20Volume126,772 shsAverage Volume224,596 shsMarket Capitalization$31.49 millionP/E RatioN/ADividend YieldN/ABeta-0.66 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Dow AgroSciences and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Arcadia Biosciences has a potential upside of 312.1% from its current price of $3.64.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesArcadia Biosciences has received 269 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArcadia Biosciences has received 251 “underperform” votes. (Add your “underperform” vote.)Community SentimentArcadia Biosciences has received 51.73% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote “Outperform” if you believe RKDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 5.07% of the stock of Arcadia Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($1.33) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Agricultural chemicals Sub-IndustryN/A SectorBasic Materials Current SymbolNASDAQ:RKDA Previous Symbol CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone530-756-7077Debt Debt-to-Equity Ratio0.45 Current Ratio4.09 Quick Ratio3.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.17 million Price / Sales26.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book2.58Profitability EPS (Most Recent Fiscal Year)($3.37) Net Income$-28,810,000.00 Net Margins-1,035.38% Return on Equity-180.70% Return on Assets-61.05%Miscellaneous Employees44 Outstanding Shares8,650,000Market Cap$31.49 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:RKDA Rates by TradingView Receive RKDA News and Ratings via Email Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter. Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions How has Arcadia Biosciences' stock been impacted by COVID-19 (Coronavirus)? Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RKDA stock has increased by 14.8% and is now trading at $3.64. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arcadia Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcadia Biosciences. When is Arcadia Biosciences' next earnings date? Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Arcadia Biosciences. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences Inc (NASDAQ:RKDA) released its quarterly earnings data on Wednesday, May, 13th. The basic materials company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.84. The basic materials company earned $0.31 million during the quarter, compared to analysts' expectations of $0.60 million. Arcadia Biosciences had a negative return on equity of 180.70% and a negative net margin of 1,035.38%. View Arcadia Biosciences' earnings history. When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work? Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for RKDA? 2 equities research analysts have issued 12 month target prices for Arcadia Biosciences' shares. Their forecasts range from $14.00 to $16.00. On average, they expect Arcadia Biosciences' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 312.1% from the stock's current price. View analysts' price targets for Arcadia Biosciences. What are Wall Street analysts saying about Arcadia Biosciences stock? Here are some recent quotes from research analysts about Arcadia Biosciences stock: 1. National Securities analysts commented, " Second Quarter Results Meet Expectations. A $5.0 million operating loss fell in line with our $4.8 million estimates. GAAP earnings were skewed by a $9.5 million non-cash gain from warrant adjustments. Excluding this, earnings fell in line with estimates. Cannabis Initiative Taking Off. The story of the earnings release was surprisingly not what has driven volume in recent days. The cannabis initiative is accelerating faster than we anticipated, with the company now expecting to derive near term revenue from sale of seed. We estimate this high margin product could conservatively deliver $3 to $5 million of revenue in 2020, with modest initial revenues coming in the fourth quarter of 2019. HB4 Approved By USDA. On August 8th, the USDA announced its approval of the HB4 soybean to be grown domestically. This is a meaningful milestone and came 12 to 24 months before we anticipated. RKDA can now identify a commercial partner and integrate the trait into domestic germplasm with field trials likely to begin in 2021 and commercial revenue in 2023. While this is a faster timeline than we expected, it does not significantly alter our estimates or valuation. Cannabis Value Still In Early Innings. We believe the most valuable revenue in agribusiness is derived from proprietary genetics, and we believe the most valuable crop in the market is cannabis. RKDA is engaged in breeding efforts to develop proprietary lines of cannabis, which we believe is a roughly 3 year process before commercialization can begin. For patient investors, we believe RKDA is in the process of generating significant value via these efforts, and we expect enhanced visibility of this potential over the next 12 to 24 months." (8/15/2019) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend. This translates into a price per share of $14.00, assuming roughly 10M shares outstanding as of end-1Q20." (6/6/2019) Has Arcadia Biosciences been receiving favorable news coverage? Media stories about RKDA stock have trended negative on Thursday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcadia Biosciences earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned news stories about the basic materials company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutArcadia Biosciences. Who are some of Arcadia Biosciences' key competitors? Some companies that are related to Arcadia Biosciences include CVR Partners (UAN), Wynnstay Group (WYN), Evogene (EVGN), Eden Research (EDEN), Bion Environmental Technologies (BNET), China Green Agriculture (CGA), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT) and ICL Group (ICL). View all competitors. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), Opko Health (OPK), Inovio Pharmaceuticals (INO), Netflix (NFLX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Yield10 Bioscience (YTEN) and Advanced Micro Devices (AMD). Who are Arcadia Biosciences' key executives? Arcadia Biosciences' management team includes the following people: Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)Ms. Sarah Reiter, Chief Commercial Officer (Age 47)Dr. Randy Shultz Ph.D., Head of R&DDr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53) When did Arcadia Biosciences IPO? (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. What is Arcadia Biosciences' stock symbol? Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA." Who are Arcadia Biosciences' major shareholders? Arcadia Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (0.19%) and Morgan Stanley (0.16%). Company insiders that own Arcadia Biosciences stock include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan and Sarah Reiter. View institutional ownership trends for Arcadia Biosciences. Which institutional investors are buying Arcadia Biosciences stock? RKDA stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, and Morgan Stanley. Company insiders that have bought Arcadia Biosciences stock in the last two years include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan, and Sarah Reiter. View insider buying and selling activity for Arcadia Biosciences. How do I buy shares of Arcadia Biosciences? Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arcadia Biosciences' stock price today? One share of RKDA stock can currently be purchased for approximately $3.64. How big of a company is Arcadia Biosciences? Arcadia Biosciences has a market capitalization of $31.49 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe. What is Arcadia Biosciences' official website? The official website for Arcadia Biosciences is www.arcadiabio.com. How can I contact Arcadia Biosciences? Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
